The current study presents the case of a 78-year-old male with concurrent chronic neutrophilic leukemia (CNL) and multiple myeloma (MM) who developed acute myeloid leukemia after two years of treatment with hydroxyurea, cyclophosphamide, prednisone and thalidomide. The patient presented with mature neutrophilic leukocytosis, hepatosplenomegaly, a high neutrophil alkaline phosphatase score and an absence of the Philadelphia chromosome or the BCR-ABL fusion gene. A bone marrow aspirate smear and biopsy indicated that the CNL coexisted with a plasma cell neoplasm. In addition, monoclonal λ-paraproteinemia was detected by serum protein immunofixation electrophoresis, and bone lesions were identified in multiple vertebrae. The patient achieved complete remission following one cycle of induction chemotherapy with the decitabine regimen in combination with the low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor (CAG) priming regimen. The occurrence of CNL and MM concurrently is extremely rare and thus, it has only been reported in a small number of cases. The occurrence of CNL and MM in the same patient as two distinct hematological malignancies indicates the neoplastic transformation of a pluripotent stem cell. Decitabine combined with the CAG priming regimen may present a good therapeutic strategy for elderly patients with secondary acute myeloid leukemia.
Introduction
Chronic neutrophilic leukemia (CNL) presents as a distinct clinicopathological entity, exhibiting the characteristics of mature neutrophilic leukocytosis and splenomegaly with bone marrow granulocytic hyperplasia without evidence of dysplasia or striking reticulin fibrosis (1) . Multiple myeloma (MM) is a condition that is associated with the monoclonal proliferation of plasma cells that have differentiated from lymphoid B cells (2) . Thus, the abnormal cell types observed in CNL and MM are markedly different, originating from myeloid and lymphoplasmacytic cell lineages, respectively (3, 4) . A small number of cases of CNL occurring concurrently with MM have been reported, however, the clinicopathological characteristics of the disease remain unclear, and the clonal cytogenetic abnormalities have not been identified in this specific group of patients. The current study presents the case of a patient with concurrent CNL and MM who subsequently developed acute myeloid leukemia. The patient achieved complete remission (CR) following induction chemotherapy with decitabine and the cytarabine, aclarubicin and granulocyte-colony stimulating factor (G-CSF) (CAG) priming regimen. Consent was obtained from the family of the patient.
Case report
A 78-year-old male presented with leukocytosis (leukocyte count, 47,500/µl; normal range, 4,000-10,000/µl) on a routine complete blood count prior to cataract surgery in The First Affiliated Hospital of Nanjing Medical University, Jiangsu Hospital, (Nanjing, China) in 2009. Hemoglobin and thrombocyte counts were within the normal ranges. The patient experienced no subjective symptoms. Moderate hepatosplenomegaly was identified, however, no lymphadenopathy was evident. A bone marrow aspirate smear revealed hypercellularity with a large number of neutrophils, including segmented neutrophils (40.4%), band forms (19.6%), myelocytes (13.6%), lymphocytes (6%) and a few rare cells, such as blast cells and plasma cells.. The peripheral blood film contained segmented neutrophils (80%), band forms (6%), lymphocytes (11%), monocytes (2%) and eosinophils (1%).
Neutrophil alkaline phosphatase staining indicated that the neutrophils were strongly positive with a high score.
Conventional cytogenetic analysis was performed on bone marrow cells using the direct method (5), as well as 24 h of non-stimulated culture of fresh heparinized bone marrow cells. R-banding results revealed that the karyotype of the patient was 46,XY [20]. Dual color dual fusion fluorescence in situ hybridization (FISH) using BCR/ABL probes (Vysis, Inc., Downers Grove, IL, USA) to detect the Philadelphia chromosome was also performed to exclude chronic myeloid leukemia (CML), and the results showed that screening for BCR/ABL fusion was negative in all 300 examined interphase cells. Polymerase chain reaction analysis was performed to determine BCR/ABL fusion gene status, which was also confirmed to be negative. Reactive neutrophilia and other myeloproliferative neoplasms were excluded by clinical and laboratory observation. A diagnosis of CNL was established according to the criteria of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues (6) and thus, the patient was administered hydroxyurea at a dose of 1 g twice per day., with the dose adjusted according to the leukocyte count.
After ~14 months, a bone marrow aspirate revealed that the number of plasma cells was increased to 6.4%, including plasmablastic, immature plasma and multinucleated plasma cells (Fig. 1 ). The bone marrow biopsy indicated the coexistence of myeloproliferative and plasma neoplasms. The abnormal plasma cells were cluster of differentiation (CD)38(+), CD138(+) and epithelial membrane antigen(+/-) ( Fig. 1 ). Karyotype analysis was repeated and again revealed a karyotype of 46,XY [15]. Interphase FISH analysis combined with magnetic-activated cell sorting (MACS), which markedly enhances the sensitivity of cytogenetic analysis, was performed. Five different probes specific for the regions containing 13q14.3, 14q32, 1q21, 1p12 and 17p13 were used to detect chromosomal aberrations. Positive values were identified for 13q14.3, 17p13 and 1q21, while negative values were identified for the probes specific for 1p13 and 14q32. Immunoglobulin (Ig) tests showed an IgM level of 0.27 g/l (normal range, 0.4-2.3 g/l), while IgG and IgA levels were within the normal ranges. The β2 microglobulin level was 5.17 mg/l (normal range, 0-3 mg/l) and the urine κ-and λ-light chains for 24 h were 70.8 and 434 mg, respectively. Serum protein immunofixation electrophoresis showed a sharp positive band for the λ-light chain subtype ( Fig. 1 ). Bone magnetic resonance imaging (MRI) indicated diffused lesions in multiple vertebrae. The concurrent existence of MM was established and thus, cyclophosphamide (50mg daily, d1-21), prednisone (30mg daily, d1-21) and thalidomide (100mg, every night) were subsequently administered for the treatment of MM. Each cycle was 1 month.
After two years, the patient's bone marrow smear demonstrated hypercellularity, with monoblast cells and promonocytes accounting for 58% of nucleated cells, indicating that the patient had progressed to acute monocytic leukemia, according to the French-American-British classification criteria ( Fig. 1) (7) . The patient achieved CR after one cycle of induction chemotherapy with the decitabine regimen (15 mg/m 2 every day, on days 1-5) combined with low-dose CAG (10 mg/m 2 cytarabine, every 12 h, on days 3-9; 10 mg aclarubicin, on days 3-6; and 200 µg/m 2 G-CSF, every day). Each cycle was 1 month. Subsequent consolidation chemotherapy (cytarabine 2g/m 2 twice daily for 3 days) was administered. The patient completed two cycles in our hospital and refused any other chemotherapy. After approximately one year, the patient relapsed and succumbed to the disease soon after.
Discussion
CNL is a rare myeloproliferative neoplasm that is characterized by persistent leukocytosis consisting of mature neutrophils, bone marrow granulocytic hyperplasia, hepatosplenomegaly and the absence of the Philadelphia chromosome or BCR-ABL fusion gene. The incidence and pathogenesis of CNL remains unclear. In ≤20% of reported cases, neutrophilia is associated with an underlying neoplasm, most frequently MM (6) . The coexistence of CNL and MM is extremely rare and thus, only a small number of cases have been reported (3, 4) . However, MM coexisting with other myeloproliferative neoplasms, including CML (8), polycythemia vera (9), essential thrombocytosis (10) and primary myelofibrosis (11) , has been reported, which may indicate an association between these distinct hematological disorders, rather than a random simultaneous occurrence.
In total, ~90% of CNL patients do not exhibit any cytogenetic abnormalities. In the remaining patients, aberrant clonal karyotypes may include add (8) , add (9) , add(21), del(20q), del(11q) and del(12p) (3) . In the present case, no clonal chromosome abnormalities were identified by the conventional cytogenetic method. However, clonal abnormalities, such as del(13q14.3), del(17p13) and add(1q21), were detected by the FISH technique using MACS to purify MM cells, which confirmed it as malignant disease.. Standen et al (3) reported two cases of CNL and concurrent MM, and identified a disproportionate excess of λ-light chain restriction in those patients. The study also reported that IgG-λ-type paraprotein and λ-light chains were identified in four and nine of the 11 previously reported cases of CNL associated with MM, respectively (4). In CML patients with concurrent MM, IgG-κ-type monoclonal paraprotein was predominant in the reported cases (9) . In the present case, the patient was confirmed as λ-type by immunofixation electrophoresis, identical to the main type (λ-type) of CNL concurrent with MM. The patient received chemotherapy for MM and disease progression did not occur for 2 years.
CNL is generally considered as a slowly progressive disorder (3); however, the survival of patients is variable, ranging between six months and >20 years. In the present study, the patient developed acute monocytic leukemia after three years, which indicated a poor prognosis. The differential diagnosis of chronic myelomonocytic leukemia was re-evaluated and excluded on the basis of a low monocyte count. The patient developed MM after the diagnosis of CNL, and succumbed to blast crisis within two years. Whether MM accelerates this process remains unclear and thus, the mechanism of this specific disorder requires further investigation.
The patient presented in this case was 78 years old and the performance status revealed that intensive chemotherapy was unsuitable. Hypermethylation, which is an epigenetic mutation that leads to a decrease in transcription via promoter regions of tumor suppressor genes causing gene silencing, has been identified as an important promoter of myeloid leukemogenesis (12) . Therefore, demethylating agents are being investigated to reverse the silencing of critical tumor suppressor genes. Decitabine is a demethylating agent that functions as a cytosine analogue. The CAG regimen, which was originally designed in Japan, rapidly became popularized in China for the treatment of acute myeloid leukemia and myelodysplastic syndrome patients due to the relatively mild toxicity exhibited by the regimen. The CR rate of acute myeloid leukemia patients treated with the CAG regimen (56.7%) appears to be marginally lower than the CR rate of patients treated with the standard daunorubicin and cytarabine regimen (DA; 45 mg/m 2 daunorubicin and 100-200 mg/m 2 cytarabine; 57-65%) (13) . However, no randomized control trial studies regarding the efficacy of the CAG and DA regimens have been performed. In the present study, the patient achieved CR following combined treatment with decitabine and the CAG regimen, which exhibited a low toxicity when compared with standard chemotherapy.
In this case, a CNL patient with concurrent MM, which was confirmed by bone marrow examination, immunofixation electrophoresis and MRI techniques, was presented. We hypothesize that the neutrophilia was a neoplasm or secondary to abnormal cytokine release from the neoplastic plasma cells or other cells regulated by plasma cells. In this case, CNL was diagnosed prior to MM, and then it transformed into acute monocytic leukemia, indicating that the neutrophilia was malignant and a diagnosis of CNL concurrent with MM was accepted. The occurrence of the two malignancies in one patient supports the hypothesis that the two malignancies are derived from hematopoietic progenitor stem cells, which may differentiate into lymphoplasmacytic or myeloid cell lines. Treatment with decitabine in combination with the CAG priming regimen may present a good treatment strategy for elderly patients with acute myeloid leukemia.
